Uncategorized
Regeneron to speed regulatory submission after positive aflibercept trial results, reports 13.9% increase in quarterly net income
Following positive 1-year outcomes from two phase 3 trials of aflibercept as a treatment for diabetic macular edema, Regeneron Pharmaceuticals announced it plans to submit an application for U.S. marketing approval this year, approximately 1 year ahead of the previous timeline, according to a company news release. The company also reported generally accepted accounting principles net income for the quarter ended June 30 of $87.4 million, compared with $76.7 million in the same period last year, for an increase of 13.9%.